Assessing the Cost-Effectiveness of Photobiomodulation for Oral Mucositis Prevention and Treatment: A Systematic Review.

IF 3.9 3区工程技术 Q2 BIOCHEMISTRY & MOLECULAR BIOLOGY Biomedicines Pub Date : 2024-10-16 DOI:10.3390/biomedicines12102366

Susell Parra-Rojas, Juliana Cassol Spanemberg, Nerea Del Mar Díaz-Robayna, Mariela Peralta-Mamani, Rocío Trinidad Velázquez Cayón

{"title":"Assessing the Cost-Effectiveness of Photobiomodulation for Oral Mucositis Prevention and Treatment: A Systematic Review.","authors":"Susell Parra-Rojas, Juliana Cassol Spanemberg, Nerea Del Mar Díaz-Robayna, Mariela Peralta-Mamani, Rocío Trinidad Velázquez Cayón","doi":"10.3390/biomedicines12102366","DOIUrl":null,"url":null,"abstract":"Background: We report on the cost-effectiveness of photobiomodulation (PBM) for the prevention and treatment of oral mucositis (OM) derived from the cytotoxic effects of antineoplastic therapy.Methods: This review followed the PRISMA 2020 guidelines. A search was conducted in PubMed, Scopus, Web of Science, Embase, and OpenGrey. Articles published before 23 July 2024, were included. Randomized controlled trials (RCTs) that included patients with head and neck cancer undergoing chemotherapy and/or radiotherapy and a placebo group compared to an intervention group (PBM) were selected. The risk of bias was evaluated using the Joanna Briggs Institute tools. The certainty of the evidence was assessed using the Grading of Recommendations Assessment, Development and Evaluation (GRADE) approach and was rated as moderate.Results: A total of 3 RCTs and 229 patients were included. PBM may represent an additional cost in the short term, but the incremental expenses derived from the cytotoxic effects of antineoplastic therapy are greater in the medium-long term. The intervention group (PBM) showed a lower incidence of severe OM compared to the control group (placebo).Conclusions: PBM is a cost-effective long-term treatment, effective in preventing severe OM and improving the quality of life of cancer patients. More RCTs following the same standardized protocols are needed (registration CDR42024498825).","PeriodicalId":8937,"journal":{"name":"Biomedicines","volume":"12 10","pages":""},"PeriodicalIF":3.9000,"publicationDate":"2024-10-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11505555/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Biomedicines","FirstCategoryId":"5","ListUrlMain":"https://doi.org/10.3390/biomedicines12102366","RegionNum":3,"RegionCategory":"工程技术","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"BIOCHEMISTRY & MOLECULAR BIOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Background: We report on the cost-effectiveness of photobiomodulation (PBM) for the prevention and treatment of oral mucositis (OM) derived from the cytotoxic effects of antineoplastic therapy.

Methods: This review followed the PRISMA 2020 guidelines. A search was conducted in PubMed, Scopus, Web of Science, Embase, and OpenGrey. Articles published before 23 July 2024, were included. Randomized controlled trials (RCTs) that included patients with head and neck cancer undergoing chemotherapy and/or radiotherapy and a placebo group compared to an intervention group (PBM) were selected. The risk of bias was evaluated using the Joanna Briggs Institute tools. The certainty of the evidence was assessed using the Grading of Recommendations Assessment, Development and Evaluation (GRADE) approach and was rated as moderate.

Results: A total of 3 RCTs and 229 patients were included. PBM may represent an additional cost in the short term, but the incremental expenses derived from the cytotoxic effects of antineoplastic therapy are greater in the medium-long term. The intervention group (PBM) showed a lower incidence of severe OM compared to the control group (placebo).

Conclusions: PBM is a cost-effective long-term treatment, effective in preventing severe OM and improving the quality of life of cancer patients. More RCTs following the same standardized protocols are needed (registration CDR42024498825).

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

评估光生物调节用于口腔黏膜炎预防和治疗的成本效益：系统综述。

背景：我们报告了光生物调节（PBM）用于预防和治疗抗肿瘤治疗的细胞毒性作用引起的口腔黏膜炎（OM）的成本效益：本综述遵循 PRISMA 2020 指南。在 PubMed、Scopus、Web of Science、Embase 和 OpenGrey 中进行了检索。纳入了 2024 年 7 月 23 日之前发表的文章。选择的随机对照试验（RCT）包括接受化疗和/或放疗的头颈部癌症患者，以及安慰剂组与干预组（PBM）的比较。采用乔安娜-布里格斯研究所（Joanna Briggs Institute）的工具对偏倚风险进行评估。证据的确定性采用建议评估、发展和评价分级法（GRADE）进行评估，被评为中等：结果：共纳入了 3 项 RCT 和 229 名患者。PBM在短期内可能会产生额外费用，但从中长期来看，抗肿瘤治疗的细胞毒性效应所产生的增量费用更大。与对照组（安慰剂）相比，干预组（PBM）严重OM的发生率较低：结论：PBM 是一种具有成本效益的长期治疗方法，能有效预防严重 OM 并改善癌症患者的生活质量。需要按照相同的标准化方案进行更多的 RCT 研究（注册号 CDR42024498825）。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊

Biomedicines Biochemistry, Genetics and Molecular Biology-General Biochemistry,Genetics and Molecular Biology

CiteScore

5.20

自引率

8.50%

发文量

2823

审稿时长

8 weeks

期刊介绍： Biomedicines (ISSN 2227-9059; CODEN: BIOMID) is an international, scientific, open access journal on biomedicines published quarterly online by MDPI.